Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Cell death"" wg kryterium: Temat


Tytuł :
Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
Autorzy :
Xie L; Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China; Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
Wang G; Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China; Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
Sang W; Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China; Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
Li J; Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China; Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
Zhang Z; Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China; Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
Li W; Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China; Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
Yan J; Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China; Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
Zhao Q; Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China; Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
Dai Y; Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China; Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China. Electronic address: .
Pokaż więcej
Źródło :
Biomaterials [Biomaterials] 2021 Feb; Vol. 269, pp. 120638. Date of Electronic Publication: 2020 Dec 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunogenic Cell Death*
Immunotherapy*
Neoplasms*/drug therapy
Doxorubicin ; Humans ; Immune Checkpoint Inhibitors ; Nanoparticles ; Polyphenols ; Programmed Cell Death 1 Receptor ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy.
Autorzy :
Zhou L; State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; China State Institute of Pharmaceutical Industry, Shanghai 201203, China.
Zhang P; State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Shandong 264000, China.
Wang H; China State Institute of Pharmaceutical Industry, Shanghai 201203, China.
Wang D; State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Shandong 264000, China.
Li Y; State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Shandong 264000, China.
Pokaż więcej
Źródło :
Accounts of chemical research [Acc Chem Res] 2020 Sep 15; Vol. 53 (9), pp. 1761-1772. Date of Electronic Publication: 2020 Aug 20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunogenic Cell Death*/drug effects
Immunotherapy*
Drug Carriers/*chemistry
Nanostructures/*chemistry
Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/pharmacology ; Enzyme Inhibitors/therapeutic use ; Humans ; Immune Checkpoint Inhibitors/chemistry ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Indoleamine-Pyrrole 2,3,-Dioxygenase/antagonists & inhibitors ; Indoleamine-Pyrrole 2,3,-Dioxygenase/chemistry ; Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism ; Ligands ; Neoplasms/therapy ; Polymers/chemistry ; Prodrugs/chemistry ; Prodrugs/pharmacology ; Prodrugs/therapeutic use ; Programmed Cell Death 1 Receptor/chemistry ; Programmed Cell Death 1 Receptor/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Early T cell infiltration is modulated by programed cell death-1 protein and its ligand (PD-1/PD-L1) interactions in murine kidney transplants.
Autorzy :
Shim YJ; Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio, USA.
Khedraki R; Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio, USA.
Dhar J; Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio, USA.
Fan R; Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio, USA.
Dvorina N; Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio, USA.
Valujskikh A; Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio, USA.
Fairchild RL; Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio, USA.
Baldwin WM 3rd; Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio, USA. Electronic address: .
Pokaż więcej
Źródło :
Kidney international [Kidney Int] 2020 Oct; Vol. 98 (4), pp. 897-905. Date of Electronic Publication: 2020 Apr 25.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Kidney Transplantation*
Programmed Cell Death 1 Receptor*
Animals ; B7-H1 Antigen ; CD8-Positive T-Lymphocytes ; Cell Death ; Ligands ; Mice ; Mice, Inbred C57BL
Czasopismo naukowe
Tytuł :
ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer.
Autorzy :
Katsurahara K; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Shiozaki A; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kosuga T; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Shimizu H; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kudou M; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Arita T; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Konishi H; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Komatsu S; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kubota T; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Fujiwara H; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Okamoto K; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kishimoto M; Department of Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Konishi E; Department of Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Otsuji E; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 Mar; Vol. 112 (3), pp. 1026-1037. Date of Electronic Publication: 2021 Jan 22.
Typ publikacji :
Journal Article
MeSH Terms :
Anoctamins/*metabolism
Biomarkers, Tumor/*metabolism
Phospholipid Transfer Proteins/*metabolism
Programmed Cell Death 1 Ligand 2 Protein/*genetics
Stomach Neoplasms/*genetics
Aged ; Anoctamins/antagonists & inhibitors ; Anoctamins/genetics ; Apoptosis/drug effects ; Apoptosis/genetics ; Apoptosis/immunology ; Biomarkers, Tumor/antagonists & inhibitors ; Biomarkers, Tumor/genetics ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Female ; Follow-Up Studies ; Gastrectomy ; Gene Expression Regulation, Neoplastic/drug effects ; Gene Knockdown Techniques ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Interferons/metabolism ; Male ; Phospholipid Transfer Proteins/antagonists & inhibitors ; Phospholipid Transfer Proteins/genetics ; Prognosis ; Programmed Cell Death 1 Receptor/metabolism ; Stomach/pathology ; Stomach/surgery ; Stomach Neoplasms/immunology ; Stomach Neoplasms/mortality ; Stomach Neoplasms/therapy ; Survival Rate
Czasopismo naukowe
Tytuł :
Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti-PD-1 Treatment Efficacy in Urothelial Carcinoma.
Autorzy :
Fukushima H; Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Yoshida S; Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Kijima T; Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Nakamura Y; Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Fukuda S; Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Uehara S; Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Yasuda Y; Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Tanaka H; Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Yokoyama M; Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Matsuoka Y; Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Fujii Y; Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Jan 07; Vol. 22 (2). Date of Electronic Publication: 2021 Jan 07.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma/*drug therapy
Carcinoma/*radiotherapy
Cisplatin/*pharmacology
Immunogenic Cell Death/*drug effects
Animals ; Antineoplastic Agents, Immunological/pharmacology ; Carcinoma/genetics ; Carcinoma/pathology ; Chemoradiotherapy ; Combined Modality Therapy ; Heterografts ; Humans ; Mice ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/genetics ; Urothelium/drug effects ; Urothelium/pathology ; Urothelium/radiation effects
Czasopismo naukowe
Tytuł :
CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
Autorzy :
Li Y; Department of Breast Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Zhang H; Department of Ultrasound, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Li Q; School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Zou P; School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Huang X; School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Wu C; Department of Breast Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China. Electronic address: .
Tan L; Department of Ultrasound, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China. Electronic address: .
Pokaż więcej
Źródło :
Cancer letters [Cancer Lett] 2020 Dec 28; Vol. 495, pp. 12-21. Date of Electronic Publication: 2020 Sep 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Breast Neoplasms/*drug therapy
CDC2 Protein Kinase/*antagonists & inhibitors
Cyclin-Dependent Kinases/*antagonists & inhibitors
Immune Checkpoint Inhibitors/*administration & dosage
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Protein Kinase Inhibitors/*administration & dosage
Animals ; Breast Neoplasms/metabolism ; Calreticulin/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Drug Synergism ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; HMGB1 Protein/metabolism ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immunogenic Cell Death ; MCF-7 Cells ; Mice ; Protein Kinase Inhibitors/pharmacology ; Protein Transport ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells.
Autorzy :
Guyon N; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France.
Garnier D; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France.
Briand J; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France.
Nadaradjane A; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France.
Bougras-Cartron G; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France.
Raimbourg J; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Department of Medical Oncology, Institut de Cancérologie de l'Ouest site René Gauducheau, Saint Herblain, France.
Campone M; Department of Medical Oncology, Institut de Cancérologie de l'Ouest site René Gauducheau, Saint Herblain, France.
Heymann D; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
Vallette FM; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France.; LabEX IGO, Université de Nantes, Nantes, France.
Frenel JS; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Department of Medical Oncology, Institut de Cancérologie de l'Ouest site René Gauducheau, Saint Herblain, France.
Cartron PF; CRCINA, INSERM, Université de Nantes, Nantes, France. .; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France. .; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France. .; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France. .; LabEX IGO, Université de Nantes, Nantes, France. .
Pokaż więcej
Źródło :
Cell death & disease [Cell Death Dis] 2020 Dec 11; Vol. 11 (12), pp. 1048. Date of Electronic Publication: 2020 Dec 11.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Apoptosis*/drug effects
Bcl-2-Like Protein 11/*metabolism
Exosomes/*metabolism
MicroRNAs/*metabolism
Neoplasms/*drug therapy
Neoplasms/*immunology
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
T-Lymphocytes/*metabolism
Aniline Compounds/pharmacology ; Aniline Compounds/therapeutic use ; Animals ; Biomarkers, Tumor/blood ; Cell Death/drug effects ; Cell Line, Tumor ; Drug Resistance, Neoplasm/drug effects ; Exosomes/drug effects ; Humans ; Mice, Nude ; MicroRNAs/genetics ; Neoplasms/blood ; Neoplasms/pathology ; Phenotype ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use ; T-Lymphocytes/drug effects ; Temozolomide/pharmacology ; Temozolomide/therapeutic use
Czasopismo naukowe
Tytuł :
Current Trends in Neurodegeneration: Cross Talks between Oxidative Stress, Cell Death, and Inflammation.
Autorzy :
Behl T; Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.
Makkar R; Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.
Sehgal A; Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.
Singh S; Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.
Sharma N; Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.
Zengin G; Department of Biology, Faculty of Science, Selcuk University Campus, Konya 42130, Turkey.
Bungau S; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.; Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410073 Oradea, Romania.
Andronie-Cioara FL; Department of Psycho-Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
Munteanu MA; Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
Brisc MC; Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
Uivarosan D; Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
Brisc C; Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Jul 11; Vol. 22 (14). Date of Electronic Publication: 2021 Jul 11.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Cell Death*
Oxidative Stress*
Inflammation/*complications
Neurodegenerative Diseases/*pathology
Animals ; Humans ; Neurodegenerative Diseases/etiology
Czasopismo naukowe
Tytuł :
Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade.
Autorzy :
Zhou M; Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Luo C; Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Zhou Z; Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Li L; Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. Electronic address: .
Huang Y; Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. Electronic address: .
Pokaż więcej
Źródło :
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2021 Jun 10; Vol. 334, pp. 248-262. Date of Electronic Publication: 2021 Apr 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
B7-H1 Antigen*/antagonists & inhibitors
Immunogenic Cell Death*
Triple Negative Breast Neoplasms*/drug therapy
Receptors, CXCR4/*antagonists & inhibitors
Humans ; Polymers ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure.
Autorzy :
Longley J; Centre for Cancer Immunology, CRUK Research Centre, University of Southampton, Southampton, UK.
Johnson PWM; Centre for Cancer Immunology, CRUK Research Centre, University of Southampton, Southampton, UK.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2021 Jun; Vol. 39 Suppl 1, pp. 39-45.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Biomarkers, Tumor*/antagonists & inhibitors
Biomarkers, Tumor*/genetics
Biomarkers, Tumor*/metabolism
Hodgkin Disease*/drug therapy
Hodgkin Disease*/genetics
Hodgkin Disease*/metabolism
Hodgkin Disease*/pathology
Neoplasm Proteins*/antagonists & inhibitors
Neoplasm Proteins*/genetics
Neoplasm Proteins*/metabolism
Precision Medicine*
Programmed Cell Death 1 Receptor*/antagonists & inhibitors
Programmed Cell Death 1 Receptor*/genetics
Programmed Cell Death 1 Receptor*/metabolism
Brentuximab Vedotin/*therapeutic use
Immune Checkpoint Inhibitors/*therapeutic use
Female ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancer.
Autorzy :
Bazzazi H; Millenium Pharmaceuticals, a wholly-owned subsidiary of Takeda Pharmaceuticals, Cambridge, MA, United States. Electronic address: .
Shahraz A; Simulations Plus Inc., Lancaster, CA, United States.
Pokaż więcej
Źródło :
Journal of theoretical biology [J Theor Biol] 2021 Aug 07; Vol. 522, pp. 110697. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji :
Journal Article
MeSH Terms :
Neoplasms*/drug therapy
Programmed Cell Death 1 Receptor*
Antibodies, Blocking ; B7-H1 Antigen ; Humans
Czasopismo naukowe
Tytuł :
The core autophagy machinery is not required for chloroplast singlet oxygen-mediated cell death in the Arabidopsis thaliana plastid ferrochelatase two mutant.
Autorzy :
Lemke MD; The School of Plant Sciences, University of Arizona, Tucson, AZ, 85721-0036, USA.
Fisher KE; The School of Plant Sciences, University of Arizona, Tucson, AZ, 85721-0036, USA.
Kozlowska MA; The School of Plant Sciences, University of Arizona, Tucson, AZ, 85721-0036, USA.
Tano DW; The School of Plant Sciences, University of Arizona, Tucson, AZ, 85721-0036, USA.
Woodson JD; The School of Plant Sciences, University of Arizona, Tucson, AZ, 85721-0036, USA. .
Pokaż więcej
Źródło :
BMC plant biology [BMC Plant Biol] 2021 Jul 19; Vol. 21 (1), pp. 342. Date of Electronic Publication: 2021 Jul 19.
Typ publikacji :
Journal Article
MeSH Terms :
Cell Death*/genetics
Arabidopsis/*metabolism
Arabidopsis Proteins/*metabolism
Autophagy/*genetics
Chloroplasts/*metabolism
Ferrochelatase/*genetics
Singlet Oxygen/*metabolism
Arabidopsis/enzymology ; Arabidopsis/genetics ; Arabidopsis Proteins/genetics ; Ferrochelatase/metabolism ; Genes, Plant ; Mutation ; Plastids/metabolism ; Seedlings ; Stress, Physiological ; Transcriptome
Czasopismo naukowe
Tytuł :
Increased PD-1 Level in Severe Cervical Injury Is Associated With the Rare Programmed Cell Death 1 ( PDCD1 ) rs36084323 A Allele in a Dominant Model.
Autorzy :
da Silva MC; Laboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Medeiros FS; Laboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
da Silva NCH; Laboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Paiva LA; Getúlio Vargas Hospital, Pernambuco Health Department, Recife, Brazil.
Gomes FODS; Laboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Costa E Silva M; Clinical Immunology Division, Department of Medicine, School of Medicine of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, Brazil.
Gomes TT; Laboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Peixoto CA; Laboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Rygaard MCV; Laboratory of Molecular Biology, IMIP Hospital, Pediatric Oncology Service, Recife, Brazil.
Menezes MLB; Department of Maternal and Child, Faculty of Medical Sciences, University of Pernambuco, Recife, Brazil.
Welkovic S; Integrated Health Center Amaury de Medeiros (CISAM), University of Pernambuco, Recife, Brazil.
Donadi EA; Clinical Immunology Division, Department of Medicine, School of Medicine of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, Brazil.
Lucena-Silva N; Laboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.; Laboratory of Molecular Biology, IMIP Hospital, Pediatric Oncology Service, Recife, Brazil.
Pokaż więcej
Źródło :
Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2021 Jul 01; Vol. 11, pp. 587932. Date of Electronic Publication: 2021 Jul 01 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cervical Intraepithelial Neoplasia*/genetics
Papillomavirus Infections*/complications
Papillomavirus Infections*/genetics
Programmed Cell Death 1 Receptor*/genetics
Alleles ; Apoptosis ; Female ; Humans
Czasopismo naukowe
Tytuł :
Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy.
Autorzy :
Liu C; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Zhou F; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yan Z; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Shen L; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Zhang X; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; School of Pharmacy, University of Chinese Academy of Sciences, Beijing, China.
He F; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Wang H; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Lu X; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yu K; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Zhao Y; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; School of Pharmacy, University of Chinese Academy of Sciences, Beijing, China.; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Zhu D; Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.; Key Laboratory of Smart Drug Delivery and Shanghai Engineering Research Center of Immune Therapy, Fudan University, Shanghai, China.
Pokaż więcej
Źródło :
British journal of pharmacology [Br J Pharmacol] 2021 Jul; Vol. 178 (13), pp. 2651-2670. Date of Electronic Publication: 2021 May 04.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
B7-H1 Antigen*/antagonists & inhibitors
Neoplasms*/drug therapy
Programmed Cell Death 1 Receptor*/antagonists & inhibitors
Animals ; Immunotherapy ; Mice ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms.
Autorzy :
MacFarlane AW 4th; Blood Cell Development and Function Program, Institute for Cancer Research, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Yeung HM; Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Alpaugh RK; Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Dulaimi E; Department of Pathology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Engstrom PF; Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Dasari A; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Campbell KS; Blood Cell Development and Function Program, Institute for Cancer Research, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA. .
Vijayvergia N; Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Jul; Vol. 70 (7), pp. 1893-1906. Date of Electronic Publication: 2021 Jan 04.
Typ publikacji :
Journal Article
MeSH Terms :
Gene Expression Regulation, Neoplastic*
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Lymphocytes, Tumor-Infiltrating/*immunology
Neuroendocrine Tumors/*immunology
Programmed Cell Death 1 Receptor/*metabolism
Receptors, Immunologic/*metabolism
Adult ; Aged ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neuroendocrine Tumors/drug therapy ; Neuroendocrine Tumors/metabolism ; Neuroendocrine Tumors/pathology ; Prognosis ; Programmed Cell Death 1 Receptor/genetics ; Prospective Studies ; Receptors, Immunologic/genetics ; Survival Rate
Czasopismo naukowe
Tytuł :
Programmed death-1 mediates venous neointimal hyperplasia in humans and rats.
Autorzy :
Sun P; Department of Vascular and Endovascular Surgery, First Affiliated Hospital of Zhengzhou University, Henan, China.
Wang Z; Department of Vascular and Endovascular Surgery, First Affiliated Hospital of Zhengzhou University, Henan, China.
Liu W; Department of Physiology, Medical School of Zhengzhou University, Henan, China.; Key Vascular Physiology and Applied Research Laboratory of Zhengzhou City, Henan, China.
Li M; Department of Vascular and Endovascular Surgery, First Affiliated Hospital of Zhengzhou University, Henan, China.
Wei S; Department of Vascular and Endovascular Surgery, First Affiliated Hospital of Zhengzhou University, Henan, China.
Xu Y; Department of Internal Medicine, First Affiliated Hospital of Zhengzhou University, Henan, China.
Qiao Z; Department of Vascular and Endovascular Surgery, First Affiliated Hospital of Zhengzhou University, Henan, China.
Wang W; Department of Physiology, Medical School of Zhengzhou University, Henan, China.; Key Vascular Physiology and Applied Research Laboratory of Zhengzhou City, Henan, China.
Fu Y; Department of Gastrointestinal Surgery, First Affiliated Hospital of Zhengzhou University, Henan, China.
Bai H; Department of Vascular and Endovascular Surgery, First Affiliated Hospital of Zhengzhou University, Henan, China.; Key Vascular Physiology and Applied Research Laboratory of Zhengzhou City, Henan, China.
Li J; School of Material Science and Engineering & Henan Key Laboratory of Advanced Magnesium Alloy & Key Laboratory of Materials Processing and Mold Technology, Ministry of Education, Zhengzhou University, Henan, China.
Pokaż więcej
Źródło :
Aging [Aging (Albany NY)] 2021 Jun 24; Vol. 13 (12), pp. 16656-16666. Date of Electronic Publication: 2021 Jun 24.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Neointima/*metabolism
Neointima/*pathology
Programmed Cell Death 1 Receptor/*metabolism
Veins/*metabolism
Veins/*pathology
Animals ; Humans ; Hyperplasia/metabolism ; Injections, Intraperitoneal ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Rats ; Small Molecule Libraries/pharmacology ; Water
Czasopismo naukowe
Tytuł :
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.
Autorzy :
Berry S; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Giraldo NA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Green BF; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Cottrell TR; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Stein JE; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Engle EL; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Xu H; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Ogurtsova A; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Roberts C; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Wang D; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Nguyen P; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Zhu Q; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Soto-Diaz S; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Loyola J; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Sander IB; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Wong PF; Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
Jessel S; Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
Doyle J; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
Signer D; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Wilton R; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
Roskes JS; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
Eminizer M; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
Park S; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Sunshine JC; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Jaffee EM; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Baras A; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
De Marzo AM; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Topalian SL; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Kluger H; Division of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT 06510, USA.
Cope L; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Lipson EJ; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Danilova L; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Anders RA; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Rimm DL; Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
Pardoll DM; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Szalay AS; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for Data Intensive Engineering and Science, Johns Hopkins University, Baltimore, MD 21218, USA.
Taube JM; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA. .; Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Pokaż więcej
Źródło :
Science (New York, N.Y.) [Science] 2021 Jun 11; Vol. 372 (6547).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Fluorescent Antibody Technique*
Antineoplastic Agents, Immunological/*therapeutic use
Biomarkers, Tumor/*analysis
Melanoma/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Adult ; Aged ; Aged, 80 and over ; Antigens, CD/analysis ; Antigens, Differentiation, Myelomonocytic/analysis ; B7-H1 Antigen/analysis ; CD8 Antigens/analysis ; Female ; Forkhead Transcription Factors/analysis ; Humans ; Immune Checkpoint Proteins/analysis ; Macrophages/chemistry ; Male ; Melanoma/chemistry ; Melanoma/immunology ; Melanoma/pathology ; Middle Aged ; Prognosis ; Programmed Cell Death 1 Receptor/analysis ; Progression-Free Survival ; Receptors, Cell Surface/analysis ; SOXE Transcription Factors/analysis ; Single-Cell Analysis ; T-Lymphocyte Subsets/chemistry ; T-Lymphocyte Subsets/immunology ; Treatment Outcome ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Design, Synthesis, and Evaluation of o -(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo .
Autorzy :
OuYang Y; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, PR China.
Gao J; State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, PR China.
Zhao L; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, PR China.
Lu J; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, PR China.
Zhong H; State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, PR China.
Tang H; State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, PR China.
Jin S; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, PR China.
Yue L; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, PR China.
Li Y; Department of Organic Chemistry, School of Science, China Pharmaceutical University, Nanjing 211198, PR China.
Guo W; State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, PR China.
Xu Q; State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, PR China.
Lai Y; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, PR China.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Jun 10; Vol. 64 (11), pp. 7646-7666. Date of Electronic Publication: 2021 May 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Design*
B7-H1 Antigen/*antagonists & inhibitors
Immune Checkpoint Inhibitors/*chemical synthesis
Nitrobenzenes/*chemistry
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Animals ; Apoptosis/drug effects ; B7-H1 Antigen/metabolism ; Binding Sites ; Cell Line, Tumor ; Female ; Humans ; Immune Checkpoint Inhibitors/metabolism ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Interferon-gamma/metabolism ; Liver Neoplasms/drug therapy ; Liver Neoplasms/pathology ; Mice ; Mice, Inbred C57BL ; Molecular Docking Simulation ; Nitrobenzenes/metabolism ; Nitrobenzenes/pharmacology ; Nitrobenzenes/therapeutic use ; Programmed Cell Death 1 Receptor/metabolism ; Structure-Activity Relationship ; T-Lymphocytes/cytology ; T-Lymphocytes/drug effects ; T-Lymphocytes/metabolism ; Tumor Microenvironment ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Autorzy :
Wang T; State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Cai S; State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Wang M; State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Zhang W; State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Zhang K; State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Chen D; State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Li Z; Center for Bioenergetics, Houston Methodist Research Institute, 6670 Bertner, Houston, Texas 77030, United States.
Jiang S; State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Jun 10; Vol. 64 (11), pp. 7390-7403. Date of Electronic Publication: 2021 May 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
B7-H1 Antigen/*metabolism
Programmed Cell Death 1 Receptor/*metabolism
Pyridines/*chemistry
Small Molecule Libraries/*chemistry
Animals ; B7-H1 Antigen/antagonists & inhibitors ; Binding Sites ; Biphenyl Compounds/chemistry ; Cell Survival/drug effects ; Drug Design ; Half-Life ; Humans ; Leukocytes, Mononuclear/cytology ; Leukocytes, Mononuclear/drug effects ; Leukocytes, Mononuclear/immunology ; Mice ; Molecular Docking Simulation ; Neoplasms/drug therapy ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Protein Interaction Maps/drug effects ; Pyridines/metabolism ; Pyridines/pharmacology ; Pyridines/therapeutic use ; Rats ; Rats, Sprague-Dawley ; Small Molecule Libraries/metabolism ; Small Molecule Libraries/pharmacology ; Small Molecule Libraries/therapeutic use ; Structure-Activity Relationship ; Xenograft Model Antitumor Assays
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies